Valuation: Outlook Therapeutics, Inc.

Market Cap 97.62M 88.94M 82.33M 74.48M 140M 9.12B 146M 995M 395M 4.93B 366M 359M 15.61B P/E 2026 *
-0.65x
P/E 2027 * -2.11x
Enterprise Value 97.62M 88.94M 82.33M 74.48M 140M 9.12B 146M 995M 395M 4.93B 366M 359M 15.61B EV / Sales 2026 *
373x
EV / Sales 2027 * 2.23x
Free-Float
86.07%
Yield 2026 *
-
Yield 2027 * -
1 day-2.74%
1 week-5.33%
Current month-16.47%
1 month-24.81%
3 months-42.19%
6 months+43.22%
Current year-75.25%
1 week 0.35
Extreme 0.35
0.45
1 month 0.35
Extreme 0.35
0.6
Current year 0.16
Extreme 0.1611
1.88
1 year 0.16
Extreme 0.1611
2.54
3 years 0.16
Extreme 0.1611
12.85
5 years 0.16
Extreme 0.1611
42.4
10 years 0.16
Extreme 0.1611
632
Manager TitleAgeSince
Chief Executive Officer 54 30/06/2025
Director of Finance/CFO 58 31/08/2026
Chief Tech/Sci/R&D Officer - 18/01/2023
Director TitleAgeSince
Director/Board Member 65 10/12/2015
Chairman 41 30/01/2025
Director/Board Member 50 30/10/2017
Date Insider Type Main position Quantity % Market Cap. Importance
01/09/26 Free

Chief Financial Officer

500,000 0.3122%
14/08/26 Buy

Chief Executive Officer

202,020 0.0832%
14/08/26 Buy

Chief Executive Officer

303,030 0.1249%
Change 5-day change 1-year change 3-year change Capi.($)
-2.74%-5.33%-79.20%-95.56% 97.62M
-2.49%-6.35%+51.07%+64.95% 65.42B
+0.51%-1.68%+7.42%+91.39% 58.91B
-2.01%-1.80%+23.40%+83.09% 55.24B
-0.56%-4.65%+13.71%+111.41% 45.66B
+0.08%-6.16%+14.59%+21.19% 41.29B
+3.61%+2.63%+21.96%+46.39% 36.82B
+5.28%-4.59%+135.22%+656.44% 34.48B
+0.11%+1.45%+78.74%+57.57% 32.5B
+1.22%+23.61%-24.98%+508.31% 31.69B
Average +0.30%-1.36%+24.19%+154.52% 40B
Weighted average by Cap. +0.22%-1.17%+33.65%+155.43%

Financials

2026 *2027 *
Net sales 262K 239K 221K 200K 375K 24.47M 392K 2.67M 1.06M 13.22M 983K 962K 41.88M 43.8M 39.9M 36.94M 33.41M 62.68M 4.09B 65.6M 446M 177M 2.21B 164M 161M 7B
Net income -65.1M -59.31M -54.91M -49.66M -93.17M -6.08B -97.51M -664M -263M -3.29B -244M -239M -10.41B -44.43M -40.48M -37.48M -33.9M -63.59M -4.15B -66.56M -453M -180M -2.24B -167M -163M -7.1B
Net Debt - -
Projected Income Statement - Annual - Outlook Therapeutics, Inc.
Logo Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.
Employees
17
Date Price Change Volume
20/11/26 US$0.3969 -1.03% 303,389
19/11/26 US$0.4010 -1.69% 6,830,989
18/11/26 US$0.4079 +13.12% 4,662,577
17/11/26 US$0.3606 -8.94% 5,300,068
16/11/26 US$0.3960 -4.12% 4,210,577
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Outlook Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.4010USD
Average target price
4.820USD
Spread / Average Target
+1,102.00%
  1. Stock Market
  2. Stocks
  3. OTLK Stock